Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David F McDermott

Showing results (11-20 of 227) with videos related to

Pageof 23
Sort By:
Expert Opinion on Biological Therapy|August 21, 2018
Ipilimumab in combination with nivolumab for the treatment of renal cell carcinomaXin Gao, David F McDermott
Hematology/Oncology Clinics of North America|July 19, 2011
Immunotherapy for renal cell carcinomaJacalyn Rosenblatt, David F McDermott
Cancer Treatment Reviews|February 2, 2010
Bevacizumab as a treatment option in advanced renal cell carcinoma: an analysis and interpretation of clinical trial dataDavid F McDermott, Daniel J George
Cancer Medicine|January 10, 2014
PD-1 as a potential target in cancer therapyDavid F McDermott, Michael B Atkins
Expert Opinion on Biological Therapy|April 23, 2004
Application of IL-2 and other cytokines in renal cancerDavid F McDermott, Michael B Atkins
Clinical Advances in Hematology & Oncology : H&O|July 28, 2017
Combined blockade of vascular endothelial growth factor and programmed death 1 pathways in advanced kidney cancerDavid J Einstein, David F McDermott
Seminars in Oncology|October 19, 2006
Interleukin-2 therapy of metastatic renal cell carcinoma--predictors of responseDavid F McDermott, Michael B Atkins
Cancer|September 19, 2019
Vascular endothelial growth factor and programmed death-1 pathway inhibitors in renal cell carcinomaCharlene M Mantia, David F McDermott
Journal for Immunotherapy of Cancer|August 27, 2025
How can we increase the value of clinical trials with immunotherapy?Michael B Atkins, David F Mcdermott
Clinical Therapeutics|March 10, 2015
Cytotoxic T-lymphocyte antigen-4 blockade in melanomaElizabeth I Buchbinder, David F McDermott
Pageof 23

Showing results (11-20 of 227) with videos related to

Sort By:
Pageof 23
Expert Opinion on Biological Therapy|August 21, 2018
Ipilimumab in combination with nivolumab for the treatment of renal cell carcinomaXin Gao, David F McDermott
Hematology/Oncology Clinics of North America|July 19, 2011
Immunotherapy for renal cell carcinomaJacalyn Rosenblatt, David F McDermott
Cancer Treatment Reviews|February 2, 2010
Bevacizumab as a treatment option in advanced renal cell carcinoma: an analysis and interpretation of clinical trial dataDavid F McDermott, Daniel J George
Cancer Medicine|January 10, 2014
PD-1 as a potential target in cancer therapyDavid F McDermott, Michael B Atkins
Expert Opinion on Biological Therapy|April 23, 2004
Application of IL-2 and other cytokines in renal cancerDavid F McDermott, Michael B Atkins
Clinical Advances in Hematology & Oncology : H&O|July 28, 2017
Combined blockade of vascular endothelial growth factor and programmed death 1 pathways in advanced kidney cancerDavid J Einstein, David F McDermott
Seminars in Oncology|October 19, 2006
Interleukin-2 therapy of metastatic renal cell carcinoma--predictors of responseDavid F McDermott, Michael B Atkins
Cancer|September 19, 2019
Vascular endothelial growth factor and programmed death-1 pathway inhibitors in renal cell carcinomaCharlene M Mantia, David F McDermott
Journal for Immunotherapy of Cancer|August 27, 2025
How can we increase the value of clinical trials with immunotherapy?Michael B Atkins, David F Mcdermott
Clinical Therapeutics|March 10, 2015
Cytotoxic T-lymphocyte antigen-4 blockade in melanomaElizabeth I Buchbinder, David F McDermott
Pageof 23